<DOC>
	<DOCNO>NCT01368887</DOCNO>
	<brief_summary>The purpose study test effectiveness DermiPsor 's DPS-102 ( test product ) patient scalp Psoroasis . The study also intend assess safety product .</brief_summary>
	<brief_title>Study Test Effectiveness New Treatment Scalp Psoriasis</brief_title>
	<detailed_description>Psoriasis non-contagious skin disorder affect 2 % world population . It estimate 26 million people U.S. Europe suffer psoriasis . Forty percent ( 40 % ) suffer psoriasis scalp . Currently , three primary modality treatment psoriasis : topical , phototherapy systemic treatment . While exist treatment provide vary degree relief illness , provide long-term cure . Additionally , evidence exist treatment may cause significant side effect . The purpose study demonstrate DermiPsor 's DPS-102 ( test product ) statistically effective treatment psoriasis current topical treatment option . It also intend assess safety DPS-102 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Male female age 18 old Patient personal history scalp psoriasis Patient treatable lesion Patient TSS score equal low 9 . Patient PGA score equal low 5 . Patient negative urine pregnancy test inclusion woman childbearing potential use efficient contraceptive ( oral contraceptive , IUD , tubal ligation ) Patient agree participate study sign write informed consent comply study requirement . Patient treat topical scalp treatment scalp psoriasis within two week prior inclusion study ( corticoid , retinoids , vitamin D derivative ) , Patient treat systemic treatment psoriasis ( biologics , methotrexate , cyclosporine , retinoids ) within one month prior inclusion study Patient take systemic niacin multivitamin within past two week Patient start modify treatment betablockers within one month prior inclusion study Patient PEG ( Poly Ethylene Glycol ) allergy Pregnant breast feed female female use contraception , Patient history hypersensitivity Dovonex/Daivonex Patient participate clinical trial within three month prior inclusion , Patients Carbamazepine Primidione ( clearance Primidione Carbamazepine may reduce concomitant use Nicotinamide ) Patient guardianship , unable understand information ( linguistic mental reason ) , unwilling give her/his inform consent participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>scalp psoriasis</keyword>
</DOC>